# Nanobiotix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanobiotix

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.nanobiotix.com/
- Total disclosed funding: $14M
- Latest round: Series C (Aug 10, 2010)
- Investors on record: 7

## About

Nanobiotix specializes in innovative cancer therapies, focusing on its lead product, NBTXR3, a radio enhancer aimed at improving radiotherapy outcomes for patients with solid tumors while preserving surrounding healthy tissue. Founded in 2003 in Paris, France, Nanobiotix develops advanced cancer treatment solutions. In?May 2026, Nanobiotix SA?raised?EUR 85 million?in?PIPE funding?from Invus Financial Advisors and Qatar Holding LLC. CEO Laurent Levy, who is also a founder, leads the company. The firm has completed 9 deals, marking its presence in the oncology therapeutics space. Nanobiotix is dedicated to developing novel cancer therapies, with a particular emphasis on NBTXR3. This first-in-class radio enhancer is designed to amplify the effects of radiotherapy by concentrating radiation in tumor cells while minimizing harm to healthy tissue. The company's innovative approach aims to improve treatment results for patients suffering from various cancers, particularly in head, neck, and lung cancers, and is positioned for global market entry, emphasizing partnerships across North America, Europe, and Asia. The company will use the May 2026 funding to finance its activity and cover working capital needs until 2029.

## Funding rounds

- Series C, Aug 10, 2010, $14M — Sudinnova, Seventure Partners, Matignon Investissement et Gestion, Karista, APICAP, Vizille Capital Innovation, Rhone-Alpes Creation

## Investors

- Sudinnova (https://capitalatlas.ai/funds/sudinnova) — Series C
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series C
- Matignon Investissement et Gestion (https://capitalatlas.ai/funds/matignon-investissement-et-gestion) — Series C
- Karista (https://capitalatlas.ai/funds/karista) — Series C
- APICAP (https://capitalatlas.ai/funds/apicap) — Series C
- Vizille Capital Innovation — Series C
- Rhone-Alpes Creation (https://capitalatlas.ai/funds/rhone-alpes-creation) — Series C